Skip to main content
Biofourmis logo

Biofourmis

Updated Mar 24, 2026

Biofourmis's full profile: funding, valuation, competitors, and the people behind the company.

🇸🇬SingaporeAcquiredAI Healthcare

Out of 100

🇸🇬

HQ

Singapore

🗓

Founded

2015

💰

Raised

$465M

🏷️

Stage

Acquired

👥

Team

100-500

Biofourmis develops AI-powered digital therapeutics and remote patient monitoring technology that combines wearable biosensor data with machine learning models to predict clinical deterioration, monitor chronic disease progression, and support clinical trial digital endpoint measurement. The Singapore company platform processes continuous physiological data streams from patients in

Is this your company? Claim it →

Key Facts

  • Biofourmis has raised a total of $465M in disclosed funding across 1 funding rounds.
  • Biofourmis was founded in 2015 by Kuldeep Singh and is headquartered in Singapore.
  • Biofourmis employs approximately 100-500 people.
  • Biofourmis operates in the AI Healthcare category and is currently at the Acquired stage.
  • Biofourmis has an Awaira Score of 73/100, ranking it among the tracked AI companies on Awaira.
  • Biofourmis's most recent funding round was a Series D of $300M closed in December 2021, led by SoftBank Vision Fund 2.

Source: Awaira · Updated Mar 24, 2026

N/A

Post-money

$465M

All rounds

73/100

2015

100-500 employees

Strengths

Strong Awaira Score of 73/100

Large team of 100-500+ employees

Established market presence (founded 2015)

Considerations

!

Valuation not publicly disclosed

Analysis based on publicly available data. Not investment advice.

⚠️ ESTIMATE
💵Est. Annual Revenue
$20M–$100M estimated ARR

Awaira estimate based on public data. Not financial advice.

How does Biofourmis stack up against competitors?

MetricBiofourmisButterfly NetworkTempusAlan
Awaira Score73/10085/10084/10083/100
Total Raised$465M$370M$1.05B$750M
ValuationN/A$957M$8.1B$5.83B
StageAcquiredPublicPublicSeries D
Founded2015201120152016
Employees100-500500-10002500500-1000
Country🇸🇬🇺🇸🇺🇸🇫🇷
K

Kuldeep Singh

Founder & CEO

View founder profile →
StageAcquired
Employees100-500
Country🇸🇬 Singapore
Connect
Inactive
1 round
Series DLatest

Led by SoftBank Vision Fund 2

$300M

Dec 2021

Frequently Asked Questions

What is Biofourmis's valuation?
A confirmed valuation hasn't been made public. This is common for Acquired-stage companies in the AI Healthcare sector.
Who invested in Biofourmis?
SoftBank Vision Fund 2, General Atlantic are among the backers. Together, they've contributed to the company's growth in the AI Healthcare sector.
When did Biofourmis last raise funding?
A Series D of $300M represents the most recent capital raise in December 2021. The round was led by SoftBank Vision Fund 2.
How many employees does Biofourmis have?
The team is roughly 100-500 people, headquartered in Singapore.
What does Biofourmis do?
Biofourmis develops AI-powered digital therapeutics and remote patient monitoring technology that combines wearable biosensor data with machine learning models to predict clinical deterioration, monitor chronic disease progression, and support clinical trial digital endpoint measurement. The Singapore company platform processes continuous physiological data streams from patients in hospital-at-home programs, enabling earlier clinical intervention and reducing avoidable readmissions for heart failure, oncology, and post-surgical patients. The company operates in the AI Healthcare sector from Singapore.
Who founded Biofourmis?
Kuldeep Singh established the company in 2015. It's based in Singapore. Kuldeep Singh serves as Founder & CEO.
Is Biofourmis profitable?
Profitability data isn't available in public filings. The company has raised $465M in total funding and operates at the Acquired stage.
Where is Biofourmis headquartered?
The headquarters sit in Singapore 🇸🇬 and was established in 2015. It competes in the AI Healthcare sector.
⚔️

Compare Biofourmis

See how Biofourmis stacks up against competitors in valuation, funding, team size, and Awaira Score.

Browse all comparisons →